로그인|회원가입|고객센터|기업교육 문의
페이지 맨 위로 이동
검색

Celltrion

Celltrion Posts Record Q3 Operating Profit of KRW 510 Billion

Dong-A Ilbo | Updated 2026.10.12
Sales jump 45.8% to KRW 1.5 trillion, with operating margin at 34%
Driven by expanded sales of high-margin follow-up products and cost improvements… “Further growth expected with Omlyclo launch in the U.S.”
Panoramic view of Celltrion’s Songdo plant in Incheon. Provided by Celltrion.
Celltrion posted its highest-ever quarterly revenue and operating profit in the third quarter of this year. Operating profit exceeded KRW 500 billion for the first time since the company was founded. Expansion in sales of new, highly profitable biosimilar products and improvements in production costs drove earnings growth.

Celltrion announced in a disclosure on the 12th that, on a consolidated basis, it recorded provisional third-quarter 2026 revenue of KRW 1.5 trillion and operating profit of KRW 510 billion. Compared with the same period a year earlier, revenue increased 45.8% and operating profit rose 69.2%. The operating margin came in at 34%, up 4.7 percentage points from the same period last year.
At the start of the year, Celltrion set operating profit targets of KRW 300 billion for the first quarter, KRW 400 billion for the second quarter, and more than KRW 500 billion for the third quarter in its management plan. According to the company, it has exceeded these targets for three consecutive quarters.

The earnings improvement was supported by stable sales of existing products and a higher revenue contribution from follow-on biosimilar product lines, which have relatively higher profitability. Enhanced production efficiency and cost reductions are also analyzed to have contributed to the increase in operating profit.

● Expanded sales in Europe and the United States…growth of follow-on products

In Europe, sales expanded mainly for the autoimmune disease treatment “Remsima SC” and the allergy treatment “Omlyclo.”

Omlyclo, currently sold in 26 European countries, recorded a market share of over 90% in Spain as of July. Celltrion expects to secure more than a 98% share in Denmark by year-end through winning national tenders.

Sales of both existing and new products are also growing in the U.S. market. As of August, “Steqima” and “Yuflyma” each held a market share of 15% and 11%, respectively. Existing products “Truxima” and “Inflectra” maintained market shares of 39% and 31%, respectively.

Celltrion stated that it is improving sales efficiency by leveraging its locally established direct sales network for existing products to support its new products.

● U.S. launch of Omlyclo…driving fourth-quarter earnings expansion

In the fourth quarter, earnings are expected to be affected by sales performance of Omlyclo, newly launched in the U.S. market.

Celltrion launched Omlyclo in the United States earlier this month. Upon launch, the product was listed as a preferred drug in the commercial formulary of Optum, one of the three largest U.S. pharmacy benefit managers (PBMs). Coverage under insurance reimbursement is scheduled to take effect in the fourth quarter, which is viewed as having secured a foundation for expanding future prescriptions.

In Europe as well, major country tenders and product supply schedules are concentrated in the second half of the year, and year-end inventory build-up demand is anticipated, leading the company to expect additional revenue growth.

A Celltrion official said, “Quarterly operating profit exceeded KRW 500 billion for the first time, and we have surpassed the quarterly profit targets set at the beginning of the year for three consecutive quarters,” adding, “We will continue to increase the share of high-margin follow-on products and improve costs, and based on the U.S. launch of Omlyclo and expanded supply in Europe, we will do our utmost to achieve our fourth-quarter and full-year business plans.”

Hwang So-young

AI-translated with ChatGPT. Provided as is; original Korean text prevails.
Popular News

경영·경제 질문은 AI 비서에게,
무엇이든 물어보세요.

Click!